Cefiderocol for Infections Caused by Multidrug-Resistant Gram-Negative Bacteria

Area of Science:

• Infectious Diseases
• Pharmacology
• Urology

Background:

• Complicated urinary tract infections (cUTIs) pose a significant challenge due to rising antibiotic resistance.
• Limited effective treatment options exist for cUTIs caused by multidrug-resistant Gram-negative bacteria.
• Cefiderocol represents a new class of cephalosporin antibiotic.

Purpose of the Study:

• To introduce cefiderocol as a new treatment option for complicated urinary tract infections (cUTIs).
• To outline the indications, dosage, and administration of cefiderocol.
• To report common adverse events associated with cefiderocol therapy.

Main Methods:

• Review of the U.S. Food and Drug Administration (FDA) approval of cefiderocol in 2019.
• Description of cefiderocol's spectrum of activity against key uropathogens.
• Information on recommended dosage and adjustments based on renal function.

Main Results:

• Cefiderocol is approved for adults (≥18 years) with cUTIs caused by specific resistant bacteria, including Escherichia coli, Klebsiella pneumoniae, Proteus mirabilis, Pseudomonas aeruginosa, and Enterobacter cloacae complex.
• The standard dose is 2g intravenously every 8 hours, infused over 3 hours.
• Dose adjustments are necessary for patients with creatinine clearance outside the 60–120 mL/min range.

Conclusions:

• Cefiderocol provides a valuable new therapeutic option for patients with difficult-to-treat cUTIs.
• Understanding cefiderocol's dosing and potential adverse effects, such as gastrointestinal symptoms, is crucial for effective clinical use.
• This antibiotic addresses a critical unmet need in managing infections caused by resistant pathogens.